ResMed CEO Sells Nearly $1.36M in Shares, Exercises Options Under 10b5-1 Plan
ResMed Chairman and CEO Michael J. Farrell sold 4,991 shares on February 9, 2026, for about $1.36 million at a weighted average price of $273.7801. The same day he exercised options to acquire 4,991 shares at $146.34, for $730,382. The transactions were made under a Rule 10b5-1 plan adopted October 31, 2024. Filings show he retains substantial dire…